GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (STU:9UA) » Definitions » Cash Flow for Dividends

NervGen Pharma (STU:9UA) Cash Flow for Dividends : €0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is NervGen Pharma Cash Flow for Dividends?

NervGen Pharma's cash flow for dividends for the three months ended in Dec. 2024 was €0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

NervGen Pharma Cash Flow for Dividends Historical Data

The historical data trend for NervGen Pharma's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Cash Flow for Dividends Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow for Dividends
Get a 7-Day Free Trial - - - - -

NervGen Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NervGen Pharma Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

NervGen Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (STU:9UA) » Definitions » Cash Flow for Dividends
Comparable Companies
TSX:EPRX NEOE:CYBN TSX:FRX TSXV:ARCH TSX:TH XCNQ:GLAB TSX:MSCL TSX:MDNA XCNQ:ONCO TSX:ONC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
NGENF:USA NGEN:Canada
Address
112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
Website
https://www.nervgen.com
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

NervGen Pharma Headlines

No Headlines